Immuneering Q1 EPS $(0.49) Misses $(0.46) Estimate
Portfolio Pulse from Benzinga Newsdesk
Immuneering reported Q1 EPS of $(0.49), missing the consensus estimate of $(0.46) by 6.52%. This represents a 3.92% improvement over last year's Q1 losses of $(0.51) per share.
May 07, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Immuneering's Q1 earnings missed estimates, reporting a loss of $(0.49) per share compared to the expected $(0.46). However, this is an improvement from the previous year's loss of $(0.51) per share.
Missing the earnings estimate typically has a negative short-term impact on a company's stock price, as it may lead to decreased investor confidence. However, the improvement over last year's losses could mitigate some negative perceptions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100